Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Longer term treatment reduces risk of repeat heart attacks

Study shows longer term treatment reduces risk of repeat heart attacks


A new international study of 21,000 people who had suffered heart attacks has shown that their risk of repeat heart attacks is significantly reduced if they are treated with a medicine called BRILINTA® (ticagrelor) in addition to aspirin and continued for up to three years, compared to the current standard of care, which is treatment with aspirin alone.

BRILINTA is a heart medication that helps stop the clumping of platelets. This reduces the chance of a blood clot forming that can reduce blood flow.

More than 15,000 New Zealanders currently suffer a heart attack each year. Recent research has shown that one in five heart attack patients will have a further heart attack, stroke or cardiovascular (CV) event in the three years following a heart attack.

A new major study, PEGASUS-TIMI 54 (PEGASUS), presented at the American College of Cardiology 64th Annual Scientific Session, and published in the New England Journal of Medicine, has shown that people who had experienced a heart attack at least one year prior to study enrolment had a reduced combined risk of cardiovascular death, repeat heart attack or stroke after being treated with BRILINTA tablets plus low dose aspirin for a longer period, compared to those treated with aspirin alone.

In this trial, at 3 years both doses of BRILINTA were shown to significantly reduce the combination of CV death, heart attack or stroke compared to treatment with aspirin alone. In addition, the reduction in CV events with both doses of BRILINTA appeared consistent across major subgroups including, but not limited to, age, sex and type of heart attack.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Dr Gerard Devlin, cardiologist at Waikato Hospital, said the study had identified a group of patients at high risk who stood to benefit from a new approach to extended treatment.
Virginia Sutherland, General Manager of AstraZeneca in New Zealand, said: “As a company we are committed to cardiovascular research and are proud to have delivered the PEGASUS study which is both one of AstraZeneca’s largest clinical trial and the first prospective trial to evaluate longer term dual antiplatelet therapy in higher risk patients with a history of a heart attack.

Major bleeding is a recognised side effect of this class of medicine. Major bleeding was higher with BRILINTA than with aspirin alone, but importantly rates of fatal bleeding were low and were similar between the patients treated with BRILINTA and those treated with aspirin alone.

Long term treatment presented challenges in managing side effects, Dr Devlin said, making it important to assess patients who were best suited for the treatment. “But the good thing in this study is that while there was an increased risk of bleeding in people treated with BRILINTA this did not result in death or intracranial haemorrhage [bleeding within the skull]”.

He also welcomed the study’s finding that the 60mg dose of BRILINTA with aspirin had similar efficacy to the 90mg dose. “That means patients may require less medication to reap its benefits, and may experience fewer side effects as a result of the lower dose.”

“The key thing for people to remember who have had a heart attack is that they need to look after themselves. Don’t smoke. People also often don’t understand the reasons for the medications they are on and why these are often life-long. I would urge patients to discuss these things with their health care professional and not to stop taking any medication without talking to them. These are lifesaving medications. “

ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.